OOIR: Observatory of International Research

Papers

(The H4-Index of Parkinsonism & Related Disorders is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Altered glymphatic system in idiopathic normal pressure hydrocephalus	95
Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics	81
Linear predictive coding distinguishes spectral EEG features of Parkinson's disease	65
Predictors of COVID-19 outcome in Parkinson's disease	61
Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging	60
Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease	57
Unmet needs in Parkinson disease: Motor and non-motor	55
Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features	54
Progressive supranuclear palsy: Advances in diagnosis and management	54
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study	52
Gut microbiome in Parkinson's disease: New insights from meta-analysis	52
Rapid worsening in Parkinson's disease may hide COVID-19 infection	46
Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression	45
The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic	44
COVID-19 in Parkinson's disease: Report on prevalence and outcome	40
Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease	40
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease	39
Machine learning-assisted neurotoxicity prediction in human midbrain organoids	39
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study	38
Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease	37
Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson's disease	37
The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension	37
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	36
Voice analysis in adductor spasmodic dysphonia: Objective diagnosis and response to botulinum toxin	35
MRI biomarkers of motor and non-motor symptoms in Parkinson's disease	33

Increased diagnostic yield in complex dystonia through exome sequencing	32
Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease	31
Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study	31
The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant	30
Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial	30
How do adenosine A2A receptors regulate motor function?	30
Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations	30